NFKB1 and cancer: Although previous reports from various human cancers support a predominantly canonical NF-κB activation pathway mostly mediated by RelA/P50 [32–37], recent data along with ours highlight the possibility for a non canonical NF-κB activation pattern in different cancers [38,39].